[Corrigendum] Chemopreventive effect of 4'‑hydroxychalcone on intestinal tumorigenesis in Apc^Min mice

• Authors:
  • Qing Chen
  • Jiahong Lei
  • Jinzhe Zhou
  • Shaoze Ma
  • Qi Huang
  • Bujun Ge

• View Affiliations

  
  Affiliations: Department of General Surgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Department of Pediatrics, State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of General Surgery, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China
• Published online on: April 20, 2021     https://doi.org/10.3892/ol.2021.12741
• Article Number: 480

• Copyright : © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Article

Oncol Lett 21: Article no. [Related article:] 213, 2021; DOI: 10.3892/ol.2021.12474

Subsequently to the publication of the above article, the authors have realized that, in Fig. 1, the chemical structure of 4’-hydroxychalcone was presented without one of its requisite double bonds.

Figure 1. Experimental design and general in vivo observations. (A) The chemical structure of 4-HC. (B) Experimental design for the evaluation of the chemopreventive effect of 4-HC in male ApcMin mice. Mice were randomly allocated into groups for oral administration with 10 mg/kg/day 4-HC (n=12) or Veh control (n=11) from 8 to 20 weeks of age. Changes in (C) body weight over time and (D) HBG levels at 20 weeks for ApcMin mice orally treated with 4-HC (n=12) or Veh (n=11). Data are presented as the mean ± SEM. *P<0.05, **P<0.01 vs. Veh. 4-HC, 4’-hydroxychalcone; ApcMin, adenomatous polyposis coli multiple intestinal neoplasia mouse model; HGB, hemoglobin; Veh, vehicle.

A corrected version of Fig. 1, including the correct chemical structure of 4’-hydroxychalcone, is shown below. The authors are grateful to the Editor of Oncology Letters for granting them the opportunity to publish this corrigendum, and regret any inconvenience caused to the readership of the Journal.